NEW YORK (GenomeWeb News) – Cepheid this week received CE marking for its Xpert CT/NG and Xpert CT tests, and the firm said it would begin shipping the tests in Europe immediately. The tests are for rapid detection and differentiation of Chlamydia trachomatis and Neisseria gonorrhea and run on Cepheid's GeneXpert System.


The Board of Directors of Becton Dickinson has declared a quarterly dividend of $.45 per share. The dividend is payable on June 29 to shareholders of record on June 8.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers test gene therapy targeting a different cancer protein in a new trial, the New York Times reports.

Pennsylvania State University researchers found that salivary microRNAs could predict which kids would have longer concussion symptoms, according to NPR.

The Associated Press reports Alex Azar, the new Department of Health and Human Services secretary nominee, made millions of dollars as a pharmaceutical executive.

In PNAS this week: immune profiling of breast cancer, transposable element patterns in rice, and more.